Tango Therapeutics, Inc. (TNGX)
22.84
-0.50
(-2.14%)
USD |
NASDAQ |
Aug 31, 16:00
22.82
-0.02
(-0.09%)
After-Hours: 20:00
Tango Therapeutics Free Cash Flow : -144.27M for June 30, 2026
Free Cash Flow Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | -144.27M |
| March 31, 2026 | -142.55M |
| December 31, 2025 | -139.93M |
| September 30, 2025 | -146.76M |
| June 30, 2025 | -149.17M |
| March 31, 2025 | -135.95M |
| December 31, 2024 | -132.26M |
| September 30, 2024 | -123.18M |
| June 30, 2024 | -120.82M |
| March 31, 2024 | -122.03M |
| December 31, 2023 | -119.51M |
| Date | Value |
|---|---|
| September 30, 2023 | -121.12M |
| June 30, 2023 | -112.86M |
| March 31, 2023 | -121.07M |
| December 31, 2022 | -116.77M |
| September 30, 2022 | -105.06M |
| June 30, 2022 | -104.44M |
| March 31, 2022 | -78.81M |
| December 31, 2021 | -61.36M |
| September 30, 2021 | -62.28M |
| June 30, 2021 | 47.47M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Revolution Medicines, Inc. | -1.232B |
| Erasca, Inc. | -98.08M |
| NovelStem International Corp. | -0.2295M |
| Brainstorm Cell Therapeutics, Inc. | -4.057M |
| Summit Therapeutics, Inc. | -458.40M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -38.87M |
| Cash from Investing (Quarterly) | -445.97M |
| Cash from Financing (Quarterly) | 672.57M |
| Free Cash Flow Per Share (Quarterly) | -0.2593 |
| Free Cash Flow to Equity (Quarterly) | -38.07M |
| Free Cash Flow to Firm (Quarterly) | -38.87M |
| Free Cash Flow Yield | -4.71% |